GlassScriptPhysician profile
Amilcar Avendano
NPI 1376569061
$12,282.48
in general payments reported to CMS, 2019-2025
43 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,531 · 2020: $1,119 · 2021: $1,126 · 2022: $2,462 · 2023: $1,436 · 2024: $1,659 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,455.63 | 2019-2025 | Cardiomems, Confirm Rx, Gallant |
| Boston Scientific Corporation | $1,116.37 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Biotronik INC. | $1,066.96 | 2019-2025 | Biomonitor, Selectra, Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $1,063.32 | 2019-2025 | |
| Amgen INC. | $814.67 | 2019-2024 | Repatha |
| Medtronic, INC. | $451.27 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Avalus |
| Astrazeneca Pharmaceuticals LP | $444.24 | 2019-2025 | Andexxa, Wainua |
| Janssen Pharmaceuticals, INC | $364.08 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $348.76 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $348.35 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.83 | 2019-2025 | Jardiance |
| Pfizer INC. | $283.36 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $255.00 | 2019-2024 | Uptravi, Opsumit |
| Imperative Care, INC | $236.14 | 2025 | Symphony Catheter |
| Impulse Dynamics (USA) INC. | $218.60 | 2023-2025 | Optimizer, Optimizer |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $157.73 | 2019-2025 | |
| Amarin Pharma, INC. | $153.06 | 2019-2022 | |
| Chiesi USA, INC. | $128.32 | 2019-2022 | |
| Lundbeck LLC | $116.43 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $114.71 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $102.03 | 2019-2022 | |
| Cardiva Medical, INC. | $80.18 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Tactile Systems Technology INC | $62.95 | 2019-2022 | |
| Astellas Pharma US INC | $57.06 | 2019-2021 | |
| Novo Nordisk INC | $53.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Cook Medical LLC | $49.96 | 2022-2025 | Zilver Ptx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.57 | 2023-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $39.15 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $35.96 | 2023-2024 | Edarbi, Edarbyclor |
| Kiniksa Pharmaceuticals, LTD. | $34.41 | 2023 | Arcalyst |
| Inari Medical, INC. | $29.96 | 2022 | |
| Baxter Healthcare | $29.87 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Preventice Services, LLC | $23.72 | 2019 | |
| Biosense Webster, INC. | $23.32 | 2024 | Na |
| Angiodynamics, INC. | $23.05 | 2025 | Alphavac |
| Alnylam Pharmaceuticals INC. | $21.57 | 2023 | Onpattro |
| Medicomp INC | $18.74 | 2024 | Telepatch Cardiac Monitor |
| Arbor Pharmaceuticals, INC. | $17.05 | 2020 | |
| Ge Healthcare | $14.58 | 2019 | |
| Esperion Therapeutics, INC. | $14.30 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.35 | 2023 | Inpefa |
| Itamar Medical INC | $13.34 | 2021 | |
| Medtronic Vascular, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amilcar Avendano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.